MIMEDX Enters Patent License Agreement with Wound Care Competitor
MIMEDX Group, Inc. has reached a settlement with a competitor regarding patent infringement allegations, resulting in a $25 million payment agreement.
Stocks · News reference
MiMedx Group Announces U.S. Court Issues Favorable Ruling In Co.'s Litigation Against FDA's Regulatory Classification Of AXIOFILL
MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced that the U.S. District Court for the Northern District of Georgia issued a favorable ruling in the Company’s litigation
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MIMEDX Announces Third Quarter 2026 Operating and Financial Results
MIMEDX Group, Inc. reported its financial results for the third quarter of 2026, highlighting a return to positive Adjusted EBITDA and a shift toward a surgical-led business model.
MiMedx, Sanara Receive U.S. Federal Trading Commission Second Request For Additional Information, Documentary Materials For Proposed Business Combination
8-K filing — MIMEDX GROUP, INC. (MDXG)
Filed: 2026-10-16 AccNo: 0001213900-26-110041 Size: 205 KB Item 8.01: Other Events